Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

Shanghai Zhongshan Hospital0 个研究点目标入组 190 人开始时间: 2026年9月20日最近更新: 2026年9月21日

适应症

干预措施

试验速览

阶段: 2 期
状态: 尚未招募
发起方
入组人数: 190
主要终点: Major Pathological Response Rate

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations. Treatment is assigned according to tumor genetic findings.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥18 years.
•Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable.
•Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.
•At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-
•Adequate cardiopulmonary and major organ function for surgery.
•Written informed consent and willingness to comply with study procedures, sample collection, and follow-up.

排除标准

•Stage III NSCLC considered unresectable by surgical assessment.
•Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years.
•Another malignancy within the previous 5 years.
•Major surgery within 28 days before the first study dose.
•Any contraindication to the assigned targeted therapy.
•Inability or unwillingness to provide informed consent or comply with study requirements.